Halozyme Therapeutics' GAAP net income for 3 months of 2022 was $60.108 million, up 2.2 times from $27.895 million in the previous year. Revenue increased 31.7% to $117.279 million compared to $89.022 million a year earlier.

Halozyme Therapeutics is in talks to buy pharmaceutical company Antares Pharma for $960 million, or $5.6 per share, sources told the WSJ. Antares develops parenteral products and technology for self-injection.

Halozyme Therapeutics' GAAP net income for 2021 was $402.71 million, up 3.1 times from $129.085 million in the prior year. Revenue increased 65.7% to $443.31 million from $267.594 million a year earlier.

Halozyme Therapeutics reported a GAAP net profit of $335.94 million for 9M 2021, up 6 times from $55.921 million in the previous year. Revenues increased 2.3 times to $341.307 million from $145.891 million a year earlier.